Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects

References

• Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, Hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589. doi:10.1016/j.joca.2019.06.011
   PubMed Web of Science ®Google Scholar
• Tang X, Wang S, Zhan S, et al. The prevalence of symptomatic knee osteoarthritis in China: results from the China health and retirement longitudinal study. Arthritis Rheumatol. 2016;68(3):648–653. doi:10.1002/art.39465
   PubMed Web of Science ®Google Scholar
• Ren Y, Hu J, Tan J, et al. Incidence and risk factors of symptomatic knee osteoarthritis among the Chinese population: analysis from a nationwide longitudinal study. BMC Public Health. 2020;20(1):1491. doi:10.1186/s12889-020-09611-7
   PubMed Web of Science ®Google Scholar
• Rafanan BS, Valdecañas BF, Lim BP, et al. Consensus recommendations for managing osteoarthritic pain with topical NSAIDs in Asia-Pacific. Pain Manag. 2018;8(2):115–128. doi:10.2217/pmt-2017-0047
   PubMed Web of Science ®Google Scholar
• Long H, Liu Q, Yin H, et al. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the global burden of disease study 2019. Arthritis Rheumatol. 2022;74(7):1172–1183. doi:10.1002/art.42089
   PubMed Web of Science ®Google Scholar
• Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38(3):225–242. doi:10.2165/00003088-200038030-00003
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888–1899. doi:10.1056/nejm199906173402407
   PubMed Web of Science ®Google Scholar
• Tacconelli S, Capone ML, Patrignani P. Clinical pharmacology of novel selective COX-2 inhibitors. Curr Pharm Des. 2004;10(6):589–601. doi:10.2174/1381612043453108
   Web of Science ®Google Scholar
• Vane JR, Botting RM. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum. 1997;26(6 Suppl 1):2–10. doi:10.1016/s0049-0172(97)80046-7
   Web of Science ®Google Scholar
• Meng Q, Zhang Z, Li F, et al. The prescription patterns and safety profiles of oral non-steroidal anti-inflammatory drugs in China: an 8-year real-life analysis. Ann Palliat Med. 2021;10(2):2224–2237. doi:10.21037/apm-20-2356
   PubMed Web of Science ®Google Scholar
• Lenzer J. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ. 2005;330(7489):440. doi:10.1136/bmj.330.7489.440
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633–1644. doi:10.1001/jama.296.13.jrv60011
   PubMed Web of Science ®Google Scholar
• Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation. 2002;106(2):167–169. doi:10.1161/01.cir.0000025261.58465.62
   Web of Science ®Google Scholar
• Jianlin H, Jieruo G, Yunfeng P, et al. A multicenter, double-blind and randomized controlled Phase II trial of imrecoxib in treatment of knee osteoarthritis. Chin Pharm J. 2011;46(22):1740–1745. Chinese.
   Google Scholar
• Dong X, Fengchun Z, Jieruo G, et al. A multicenter double blind and randomized controlled Phase III trial of imrecoxib in the treatment of knee osteoarthritis. Chin J Allergy Clin Immunol. 2014;8(03):205–210. Chinese. doi:10.3969/j.issn.1673-8705.2014.03.008
   Google Scholar
• Xixi Z, Wenjie Z, Fengchun Z. A multicenter open-labeled phase IV trial of imrecoxib in the treatment of knee osteoarthritis. Chin J Rheumatol. 2016;20(11):730–733. Chinese. doi:10.3760/cma.j.issn.1007-7480.2016.11.003
   Google Scholar
• Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin. 2004;25(7):927–931.
   PubMed Web of Science ®Google Scholar
• Hou X, Zhou J, Yu S, et al. Differences in the in vivo and in vitro metabolism of imrecoxib in humans: formation of the rate-limiting aldehyde intermediate. Drug Metab Dispos. 2018;46(9):1320–1328. doi:10.1124/dmd.118.081182
   Web of Science ®Google Scholar
• Feng Z, Chu F, Guo Z, Sun P. Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009;19(8):2270–2272. doi:10.1016/j.bmcl.2009.02.090
   Web of Science ®Google Scholar
• Li Q, Huang HH, Dong Y, Zhong DF. 采用重组人源CYP酶研究艾瑞昔布的体外羟基化代谢 [Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs]. Yao Xue Xue Bao. 2005;40(10):912–915. doi:10.3321/j.issn:0513-4870.2005.10.010. Chinese.
   Google Scholar
• Hou X, Dai X, Yang Y, Zhang Y, Zhong D, Chen X. Simultaneous determination of imrecoxib and its two active metabolites in plasma of hepatic impairment patients by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1122–1123:58–63. doi:10.1016/j.jchromb.2019.05.018
   Web of Science ®Google Scholar
• Cho SJ, Stout-Delgado HW. Aging and Lung Disease. Annu Rev Physiol. 2020;82:433–459. doi:10.1146/annurev-physiol-021119-034610
   PubMed Web of Science ®Google Scholar
• Koren G, Nordon G, Radinsky K, Shalev V. Clinical pharmacology of old age. Expert Rev Clin Pharmacol. 2019;12(8):749–755. doi:10.1080/17512433.2019.1632188
   PubMed Web of Science ®Google Scholar
• Thürmann PA. Pharmacodynamics and pharmacokinetics in older adults. Curr Opin Anaesthesiol. 2020;33(1):109–113. doi:10.1097/aco.0000000000000814
   PubMed Web of Science ®Google Scholar
• Maher D, Ailabouni N, Mangoni AA, Wiese MD, Reeve E. Alterations in drug disposition in older adults: a focus on geriatric syndromes. Expert Opin Drug Metab Toxicol. 2021;17(1):41–52. doi:10.1080/17425255.2021.1839413
   PubMed Web of Science ®Google Scholar
• Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol. 2015;11(4):491–508. doi:10.1517/17425255.2015.1004310
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76. doi:10.1080/03602530902722679
   PubMed Web of Science ®Google Scholar
• Pei Q, Xie JL, Huang J, et al. Pharmacokinetic study of imrecoxib in patients with renal insufficiency. Eur J Clin Pharmacol. 2019;75(10):1355–1360. doi:10.1007/s00228-019-02698-x
   Web of Science ®Google Scholar
• Zongru G. Discovery of imrecoxib. Chin J New Drugs. 2012;21(03):223–230. Chinese.
   Google Scholar
• Xu HY, Xie ZY, Zhang P, et al. Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib. Acta Pharmacol Sin. 2006;27(3):372–380. doi:10.1111/j.1745-7254.2006.00265.x
   Web of Science ®Google Scholar
• Xu H, Zhang Y, Sun Y, et al. Metabolism and excretion of imrecoxib in rat. Xenobiotica. 2006;36(5):441–455. doi:10.1080/00498250600595524
   PubMed Web of Science ®Google Scholar
• Khan MS, Roberts MS. Challenges and innovations of drug delivery in older age. Adv Drug Deliv Rev. 2018;135:3–38. doi:10.1016/j.addr.2018.09.003
   PubMed Web of Science ®Google Scholar
• Li Y, Wang J, Huang J, et al. Dose investigation of imrecoxib in patients with renal insufficiency based on modelling and simulation. Eur J Pharm Sci. 2020;152:105449. doi:10.1016/j.ejps.2020.105449
   Web of Science ®Google Scholar
• Shen F, Bai AP, Guo ZR, Cheng GF. Inhibitory effect of 3,4-diaryl-3-pyrrolin-2-one derivatives on cyclooxygenase 1 and 2 in murine peritoneal macrophages. Acta Pharmacol Sin. 2002;23(8):762–768.
   Web of Science ®Google Scholar
• Jianlin H, Yunfeng P, Yu-qiong W, Hui S, Jieruo G. Phase I clinical tolerability of imrecoxib. Chin Pharm J. 2011;46(21):1670–1673. Chinese.
   Google Scholar
• Jiang Y, Qi L, Liu J, et al. Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial. Ann Transl Med. 2021;9(6):469. doi:10.21037/atm-21-264
   PubMed Web of Science ®Google Scholar